Preliminary Findings on the Use of Targeted Therapy in Combination with Sodium Phenylbutyrate in Recurrent Advanced Pancreatic Cancer—A Potential Strategy for Improved Survival
Read full paper at： http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50936#.VFCBKlfHRK0 Author(s) Stanislaw R. Burzynski , Tomasz J. Janicki , Gregory S. Burzynski , Sheldon Brookman Affiliation(s) Burzynski Clinic, Houston, TX, USA . ABSTRACT Metastatic pancreatic cancer carries an estimated five-year survival rate of only 2%. Gemcitabine-based chemotherapy remains a first-line standard-of-care treatment for elderly patients with advanced pancreatic cancer. Combination chemotherapy FOLFIRINOX offers better results, but it is not recommended for the older patient population due to substantial toxicity. Standard-of-care second-line treatment is not yet established and is used in approximate...